0	0	1998-09-22	CD	O	O	B-Num
0	1	09	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	48	CD	O	B-NP	I-Num
0	4	ANTI-BALDNESS	NNP	O	I-NP	O
0	5	DRUG	NN	O	I-NP	O
0	6	IS	VBZ	O	B-VP	O
0	7	STUDIED	NNP	O	B-NP	O
0	8	FOR	IN	O	B-PP	O
0	9	USE	NNP	O	O	O
0	10	AGAINST	NNP	O	O	O
0	11	PROSTATE	NNP	O	O	B-Jour
0	12	CANCER	NNP	O	O	O

1	0	SAN	NNP	O	O	O
1	1	ANTONIO	NNP	O	O	O
1	2	_	NN	O	O	O
1	3	Almost	RB	O	B-NP	O
1	4	25	CD	O	I-NP	B-Num
1	5	years	NNS	O	I-NP	I-Num
1	6	ago	IN	O	O	O
1	7	COMMA	COMMA	O	O	O
1	8	doctors	NNS	O	B-NP	B-ProfTitle
1	9	published	VBD	O	B-VP	O
1	10	an	DT	O	B-NP	O
1	11	account	NN	O	I-NP	O
1	12	of	IN	O	B-PP	O
1	13	a	DT	O	B-NP	O
1	14	rare	JJ	O	I-NP	O
1	15	genetic	JJ	O	I-NP	B-Medical
1	16	disorder	NN	O	I-NP	B-Medical
1	17	among	IN	O	B-PP	O
1	18	some	DT	O	B-NP	O
1	19	children	NNS	O	I-NP	O
1	20	in	IN	O	B-PP	O
1	21	the	DT	O	B-NP	O
1	22	Dominican	NNP	O	I-NP	B-LocCoun
1	23	Republic	NNP	O	I-NP	I-LocCoun
1	24	.	.	O	O	O

2	0	The	DT	O	B-NP	O
2	1	children	NNS	O	I-NP	O
2	2	were	VBD	O	B-VP	O
2	3	born	VBN	O	I-VP	O
2	4	sexually	RB	O	O	O
2	5	``	``	O	O	O
2	6	ambiguousCOMMA	NN	O	O	O
2	7	''	''	O	O	O
2	8	but	CC	O	O	O
2	9	developed	VBD	O	B-VP	O
2	10	as	IN	O	B-PP	O
2	11	normal	JJ	O	B-NP	O
2	12	males	NNS	O	I-NP	O
2	13	after	IN	O	B-PP	O
2	14	puberty	NN	O	B-NP	B-Medical
2	15	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	Dominican	NNP	O	I-NP	B-Org
3	2	Republic	NNP	O	I-NP	I-Org
3	3	research	NN	O	I-NP	O
3	4	``	``	O	O	O
3	5	eventually	RB	O	O	O
3	6	led	VBN	O	B-VP	O
3	7	to	TO	O	B-PP	O
3	8	the	DT	O	B-NP	O
3	9	discovery	NN	O	I-NP	O
3	10	that	IN	O	O	O
3	11	the	DT	O	B-NP	O
3	12	prostate	NN	O	I-NP	B-Jour
3	13	actually	RB	O	O	O
3	14	is	VBZ	O	B-VP	O
3	15	present	JJ	O	O	O
3	16	in	IN	O	B-PP	O
3	17	male	JJ	O	B-NP	O
3	18	and	CC	O	I-NP	O
3	19	female	JJ	O	I-NP	O
3	20	fetuses	NNS	O	I-NP	O
3	21	early	JJ	O	O	O
3	22	in	IN	O	B-PP	O
3	23	development	NN	O	B-NP	O
3	24	COMMA	COMMA	O	O	O
3	25	but	CC	O	O	O
3	26	it	PRP	O	B-NP	O
3	27	requires	VBZ	O	B-VP	O
3	28	androgen	NN	O	B-NP	O
3	29	stimulation	NN	O	I-NP	O
3	30	for	IN	O	O	O
3	31	it	PRP	O	B-NP	O
3	32	to	TO	O	B-PP	O
3	33	developCOMMA	NN	O	B-NP	O
3	34	''	''	O	O	O
3	35	said	VBD	O	B-VP	O
3	36	Dr.	NNP	O	B-NP	B-ProfTitle
3	37	Ian	NNP	O	I-NP	B-Peop
3	38	Thompson	NNP	O	I-NP	I-Peop
3	39	COMMA	COMMA	O	O	O
3	40	chief	NN	O	B-NP	B-ProfTitle
3	41	of	IN	O	B-PP	O
3	42	surgery	NN	O	B-NP	O
3	43	at	IN	O	B-PP	O
3	44	Brooks	NNP	O	B-NP	B-LocCit
3	45	Air	NNP	O	I-NP	B-OrgPolBody
3	46	Force	NNP	O	I-NP	I-OrgPolBody
3	47	Base	NNP	O	I-NP	O
3	48	and	CC	O	O	O
3	49	clinical	JJ	O	B-NP	B-Medical
3	50	director	NN	O	I-NP	B-ProfTitle
3	51	of	IN	O	B-PP	O
3	52	the	DT	O	B-NP	O
3	53	national	JJ	O	I-NP	O
3	54	study	NN	O	I-NP	O
3	55	.	.	O	O	O

4	0	That	DT	O	B-NP	O
4	1	observation	NN	O	I-NP	O
4	2	led	VBD	O	B-VP	O
4	3	to	TO	O	B-PP	O
4	4	the	DT	O	B-NP	O
4	5	understanding	NN	O	I-NP	O
4	6	that	IN	O	O	O
4	7	5	CD	O	B-NP	B-Num
4	8	alpha-reductase	NN	O	I-NP	O
4	9	COMMA	COMMA	O	O	O
4	10	a	DT	O	B-NP	O
4	11	metabolite	NN	O	I-NP	B-Medical
4	12	of	IN	O	B-PP	O
4	13	testosterone	NN	O	B-NP	O
4	14	COMMA	COMMA	O	O	O
4	15	the	DT	O	B-NP	O
4	16	male	JJ	O	I-NP	O
4	17	sex	NN	O	I-NP	O
4	18	hormone	NN	O	I-NP	B-Medical
4	19	COMMA	COMMA	O	O	O
4	20	leads	VBZ	O	B-VP	O
4	21	to	TO	O	B-PP	O
4	22	the	DT	O	B-NP	O
4	23	development	NN	O	I-NP	O
4	24	of	IN	O	B-PP	O
4	25	the	DT	O	B-NP	O
4	26	prostate	NN	O	I-NP	B-Jour
4	27	in	IN	O	B-PP	O
4	28	males	NNS	O	B-NP	O
4	29	.	.	O	O	O

5	0	Even	RB	O	O	O
5	1	as	IN	O	B-PP	O
5	2	adults	NNS	O	B-NP	O
5	3	COMMA	COMMA	O	O	O
5	4	the	DT	O	B-NP	O
5	5	men	NNS	O	I-NP	O
5	6	with	IN	O	B-PP	O
5	7	the	DT	O	B-NP	O
5	8	genetic	JJ	O	I-NP	B-Medical
5	9	disorder	NN	O	I-NP	B-Medical
5	10	could	MD	O	B-VP	O
5	11	not	RB	O	I-VP	O
5	12	properly	RB	O	I-VP	O
5	13	make	VBP	O	I-VP	O
5	14	5	CD	O	B-NP	B-Num
5	15	alpha-reductase	NN	O	I-NP	O
5	16	.	.	O	O	O

6	0	They	PRP	O	B-NP	O
6	1	had	VBD	O	B-VP	O
6	2	a	DT	O	B-NP	O
6	3	small	JJ	O	I-NP	O
6	4	prostate	NN	O	I-NP	B-Jour
6	5	gland	NN	O	I-NP	O
6	6	throughout	IN	O	B-PP	O
6	7	life	NN	O	B-NP	O
6	8	COMMA	COMMA	O	O	O
6	9	did	VBD	O	B-VP	O
6	10	not	RB	O	I-VP	O
6	11	develop	VB	O	I-VP	O
6	12	benign	JJ	O	B-NP	B-Medical
6	13	prostate	NN	O	I-NP	B-Jour
6	14	enlargement	NN	O	I-NP	O
6	15	or	CC	O	I-NP	O
6	16	prostate	NN	O	I-NP	B-Jour
6	17	cancer	NN	O	I-NP	B-Medical
6	18	.	.	O	O	O

7	0	Nor	CC	O	O	O
7	1	did	VBD	O	O	O
7	2	they	PRP	O	B-NP	O
7	3	develop	VBP	O	B-VP	O
7	4	male	JJ	O	B-NP	O
7	5	pattern	NN	O	I-NP	O
7	6	baldness	NN	O	I-NP	B-Medical
7	7	or	CC	O	I-NP	O
7	8	acne	NN	O	I-NP	B-Medical
7	9	.	.	O	O	O

8	0	Research	NNP	O	B-NP	B-OrgCorp
8	1	into	IN	O	B-PP	O
8	2	that	DT	O	B-NP	O
8	3	phenomenon	NN	O	I-NP	O
8	4	eventually	RB	O	O	O
8	5	led	VBD	O	B-VP	O
8	6	to	TO	O	B-PP	O
8	7	the	DT	O	B-NP	O
8	8	drug	NN	O	I-NP	B-Medical
8	9	Proscar	NNP	O	I-NP	O
8	10	COMMA	COMMA	O	O	O
8	11	used	VBD	O	B-VP	O
8	12	to	TO	O	B-VP	O
8	13	treat	VB	O	I-VP	O
8	14	prostate	NN	O	B-NP	B-Jour
8	15	disease	NN	O	I-NP	B-Medical
8	16	and	CC	O	O	O
8	17	male-pattern	JJ	O	B-NP	O
8	18	baldness	NN	O	I-NP	B-Medical
8	19	.	.	O	O	O

9	0	The	DT	O	B-NP	O
9	1	drug	NN	O	I-NP	B-Medical
9	2	also	RB	O	O	O
9	3	is	VBZ	O	B-VP	O
9	4	being	VBG	O	I-VP	O
9	5	studied	VBN	O	I-VP	O
9	6	in	IN	O	B-PP	O
9	7	more	JJR	O	B-NP	O
9	8	than	IN	O	I-NP	O
9	9	1COMMA500	CD	O	I-NP	B-Num
9	10	healthy	JJ	O	I-NP	O
9	11	San	NNP	O	I-NP	B-LocCit
9	12	Antonio	NNP	O	I-NP	I-LocCit
9	13	men	NNS	O	I-NP	O
9	14	to	TO	O	B-VP	O
9	15	see	VB	O	I-VP	O
9	16	if	IN	O	O	O
9	17	it	PRP	O	B-NP	O
9	18	will	MD	O	B-VP	O
9	19	prevent	VB	O	I-VP	O
9	20	prostate	NN	O	B-NP	B-Jour
9	21	cancer	NN	O	I-NP	B-Medical
9	22	.	.	O	O	O

10	0	The	DT	O	B-NP	O
10	1	Prostate	NNP	O	I-NP	B-Jour
10	2	Cancer	NNP	O	I-NP	O
10	3	Prevention	NNP	O	I-NP	B-Peop
10	4	Trial	NNP	O	I-NP	I-Peop
10	5	is	VBZ	O	B-VP	O
10	6	a	DT	O	B-NP	O
10	7	seven-year	JJ	O	I-NP	O
10	8	study	NN	O	I-NP	O
10	9	of	IN	O	B-PP	O
10	10	18COMMA882	CD	O	B-NP	B-Num
10	11	men	NNS	O	I-NP	O
10	12	across	IN	O	B-PP	O
10	13	the	DT	O	B-NP	O
10	14	country	NN	O	I-NP	O
10	15	.	.	O	O	O

11	0	San	NNP	O	B-NP	B-LocCit
11	1	Antonio	NNP	O	I-NP	I-LocCit
11	2	has	VBZ	O	B-VP	O
11	3	the	DT	O	B-NP	O
11	4	largest	JJS	O	I-NP	O
11	5	pool	NN	O	I-NP	B-Sport
11	6	of	IN	O	B-PP	O
11	7	volunteers	NNS	O	B-NP	O
11	8	COMMA	COMMA	O	O	O
11	9	with	IN	O	B-PP	O
11	10	the	DT	O	B-NP	O
11	11	Brooke	NNP	O	I-NP	B-Peop
11	12	Army	NNP	O	I-NP	B-OrgPolBody
11	13	Medical	NNP	O	I-NP	B-OrgCorp
11	14	Center	NNP	O	I-NP	B-LocStruct
11	15	and	CC	O	O	O
11	16	Wilford	NNP	O	B-NP	B-LocStruct
11	17	Hall	NNP	O	I-NP	I-LocStruct
11	18	Medical	NNP	O	I-NP	I-LocStruct
11	19	Center	NNP	O	I-NP	I-LocStruct
11	20	participating	VBG	O	B-VP	O
11	21	.	.	O	O	O

12	0	If	IN	O	O	O
12	1	the	DT	O	B-NP	O
12	2	drug	NN	O	I-NP	B-Medical
12	3	is	VBZ	O	B-VP	O
12	4	shown	VBN	O	I-VP	O
12	5	to	TO	O	I-VP	O
12	6	prevent	VB	O	I-VP	O
12	7	prostate	NN	O	B-NP	B-Jour
12	8	cancer	NN	O	I-NP	B-Medical
12	9	with	IN	O	B-PP	O
12	10	minimum	JJ	O	B-NP	O
12	11	side	NN	O	I-NP	O
12	12	effects	NNS	O	I-NP	O
12	13	COMMA	COMMA	O	O	O
12	14	it	PRP	O	B-NP	O
12	15	will	MD	O	B-VP	O
12	16	provide	VB	O	I-VP	O
12	17	doctors	NNS	O	B-NP	B-ProfTitle
12	18	and	CC	O	I-NP	O
12	19	patients	NNS	O	I-NP	O
12	20	with	IN	O	B-PP	O
12	21	a	DT	O	B-NP	O
12	22	powerful	JJ	O	I-NP	O
12	23	tool	NN	O	I-NP	O
12	24	against	IN	O	B-PP	O
12	25	the	DT	O	B-NP	O
12	26	second	JJ	O	I-NP	B-Num
12	27	deadliest	JJS	O	I-NP	O
12	28	cancer	NN	O	I-NP	B-Medical
12	29	killer	NN	O	I-NP	O
12	30	of	IN	O	B-PP	O
12	31	men	NNS	O	B-NP	O
12	32	.	.	O	O	O

13	0	San	NNP	O	B-NP	B-LocCit
13	1	Antonio	NNP	O	I-NP	I-LocCit
13	2	researchers	NNS	O	I-NP	B-ProfTitle
13	3	also	RB	O	O	O
13	4	are	VBP	O	B-VP	O
13	5	looking	VBG	O	I-VP	O
13	6	for	IN	O	B-PP	O
13	7	the	DT	O	B-NP	O
13	8	genes	NNS	O	I-NP	O
13	9	responsible	JJ	O	O	O
13	10	for	IN	O	B-PP	O
13	11	prostate	NN	O	B-NP	B-Jour
13	12	cancer	NN	O	I-NP	B-Medical
13	13	.	.	O	O	O

14	0	The	DT	O	B-NP	O
14	1	San	NNP	O	I-NP	B-LocCit
14	2	Antonio	NNP	O	I-NP	I-LocCit
14	3	familial	JJ	O	I-NP	O
14	4	prostate	NN	O	I-NP	B-Jour
14	5	cancer	NN	O	I-NP	B-Medical
14	6	study	NN	O	I-NP	O
14	7	has	VBZ	O	B-VP	O
14	8	enrolled	VBN	O	I-VP	O
14	9	28	CD	O	B-NP	B-Num
14	10	families	NNS	O	I-NP	O
14	11	COMMA	COMMA	O	O	O
14	12	each	DT	O	B-NP	O
14	13	with	IN	O	B-PP	O
14	14	two	CD	O	B-NP	B-Num
14	15	or	CC	O	I-NP	O
14	16	more	JJR	O	I-NP	O
14	17	members	NNS	O	I-NP	O
14	18	with	IN	O	B-PP	O
14	19	early	JJ	O	B-NP	O
14	20	onset	NN	O	I-NP	O
14	21	of	IN	O	B-PP	O
14	22	the	DT	O	B-NP	O
14	23	disease	NN	O	I-NP	B-Medical
14	24	.	.	O	O	O

15	0	The	DT	O	B-NP	O
15	1	study	NN	O	I-NP	O
15	2	was	VBD	O	B-VP	O
15	3	originally	RB	O	I-VP	O
15	4	designed	VBN	O	I-VP	O
15	5	to	TO	O	I-VP	O
15	6	focus	VB	O	I-VP	O
15	7	on	IN	O	B-PP	O
15	8	Mexican-American	JJ	O	B-NP	O
15	9	families	NNS	O	I-NP	O
15	10	COMMA	COMMA	O	O	O
15	11	but	CC	O	O	O
15	12	only	RB	O	B-NP	O
15	13	two	CD	O	I-NP	B-Num
15	14	have	VBP	O	B-VP	O
15	15	enrolled	VBN	O	I-VP	O
15	16	COMMA	COMMA	O	O	O
15	17	said	VBD	O	B-VP	O
15	18	Dr.	NNP	O	B-NP	B-ProfTitle
15	19	Rosemarie	NNP	O	I-NP	B-Peop
15	20	Plaetke	NNP	O	I-NP	I-Peop
15	21	COMMA	COMMA	O	O	O
15	22	assistant	JJ	O	B-NP	B-ProfTitle
15	23	professor	NN	O	I-NP	B-ProfTitle
15	24	of	IN	O	B-PP	O
15	25	cellular	JJ	O	B-NP	O
15	26	and	CC	O	I-NP	O
15	27	structural	JJ	O	I-NP	O
15	28	biology	NN	O	I-NP	O
15	29	at	IN	O	B-PP	O
15	30	the	DT	O	B-NP	O
15	31	University	NNP	O	I-NP	B-OrgUniv
15	32	of	IN	O	B-PP	I-OrgUniv
15	33	Texas	NNP	O	B-NP	I-OrgUniv
15	34	Health	NNP	O	I-NP	O
15	35	Science	NNP	O	I-NP	O
15	36	Center	NNP	O	I-NP	O
15	37	.	.	O	O	O

16	0	``	``	O	O	O
16	1	Often	RB	O	O	O
16	2	we	PRP	O	B-NP	O
16	3	have	VBP	O	B-VP	O
16	4	Mexican-American	JJ	O	B-NP	O
16	5	prostate	NN	O	I-NP	B-Jour
16	6	cancer	NN	O	I-NP	B-Medical
16	7	patients	NNS	O	I-NP	O
16	8	who	WP	O	B-NP	O
16	9	want	VBP	O	B-VP	O
16	10	to	TO	O	I-VP	O
16	11	participate	VB	O	I-VP	O
16	12	.	.	O	O	O

17	0	However	RB	O	O	O
17	1	COMMA	COMMA	O	O	O
17	2	willingness	NN	O	B-NP	O
17	3	of	IN	O	B-PP	O
17	4	relatives	NNS	O	B-NP	O
17	5	to	TO	O	B-VP	O
17	6	be	VB	O	I-VP	O
17	7	enrolled	VBN	O	I-VP	O
17	8	in	IN	O	B-PP	O
17	9	the	DT	O	B-NP	O
17	10	study	NN	O	I-NP	O
17	11	is	VBZ	O	B-VP	O
17	12	lowCOMMA	NN	O	B-NP	O
17	13	''	''	O	O	O
17	14	she	PRP	O	B-NP	O
17	15	said	VBD	O	B-VP	O
17	16	.	.	O	O	O

18	0	Other	JJ	O	B-NP	O
18	1	researchers	NNS	O	I-NP	B-ProfTitle
18	2	are	VBP	O	B-VP	O
18	3	working	VBG	O	I-VP	O
18	4	on	IN	O	B-PP	O
18	5	developing	VBG	O	B-VP	O
18	6	new	JJ	O	B-NP	O
18	7	therapies	NNS	O	I-NP	O
18	8	_	NN	O	I-NP	O
18	9	or	CC	O	O	O
18	10	improving	VBG	O	B-VP	O
18	11	existing	VBG	O	B-NP	O
18	12	ones	NNS	O	I-NP	O
18	13	_	NN	O	O	O
18	14	for	IN	O	B-PP	O
18	15	prostate	NN	O	B-NP	B-Jour
18	16	cancer	NN	O	I-NP	B-Medical
18	17	.	.	O	O	O

19	0	Dr.	NNP	O	B-NP	B-ProfTitle
19	1	Michael	NNP	O	I-NP	B-Peop
19	2	Sarosdy	NNP	O	I-NP	I-Peop
19	3	COMMA	COMMA	O	O	O
19	4	a	DT	O	B-NP	O
19	5	local	JJ	O	I-NP	O
19	6	urologist	NN	O	I-NP	O
19	7	COMMA	COMMA	O	O	O
19	8	is	VBZ	O	B-VP	O
19	9	looking	VBG	O	I-VP	O
19	10	at	IN	O	B-PP	O
19	11	an	DT	O	B-NP	O
19	12	alternative	JJ	O	I-NP	B-Medical
19	13	drug	NN	O	I-NP	B-Medical
19	14	for	IN	O	B-PP	O
19	15	patients	NNS	O	B-NP	O
19	16	after	IN	O	O	O
19	17	they	PRP	O	B-NP	O
19	18	've	VBP	O	B-VP	O
19	19	undergone	VBN	O	I-VP	O
19	20	primary	JJ	O	B-NP	O
19	21	treatment	NN	O	I-NP	O
19	22	for	IN	O	B-PP	O
19	23	their	PP$	O	B-NP	O
19	24	cancer	NN	O	I-NP	B-Medical
19	25	.	.	O	O	O

20	0	Sarosdy	NNP	O	B-NP	B-Peop
20	1	is	VBZ	O	B-VP	O
20	2	exploring	VBG	O	I-VP	O
20	3	whether	IN	O	O	O
20	4	high	JJ	O	B-NP	O
20	5	doses	NNS	O	I-NP	O
20	6	of	IN	O	B-PP	O
20	7	a	DT	O	B-NP	O
20	8	single	JJ	O	I-NP	O
20	9	drug	NN	O	I-NP	B-Medical
20	10	COMMA	COMMA	O	O	O
20	11	Casodex	NNP	O	B-NP	O
20	12	COMMA	COMMA	O	O	O
20	13	can	MD	O	B-VP	O
20	14	be	VB	O	I-VP	O
20	15	effective	JJ	O	O	O
20	16	with	IN	O	B-PP	O
20	17	fewer	JJR	O	B-NP	O
20	18	side	NN	O	I-NP	O
20	19	effects	NNS	O	I-NP	O
20	20	such	JJ	O	B-PP	O
20	21	as	IN	O	I-PP	O
20	22	muscle	NN	O	B-NP	O
20	23	wasting	NN	O	I-NP	O
20	24	COMMA	COMMA	O	O	O
20	25	loss	NN	O	B-NP	O
20	26	of	IN	O	B-PP	O
20	27	muscle	NN	O	B-NP	O
20	28	mass	NN	O	I-NP	O
20	29	and	CC	O	I-NP	O
20	30	bone	NN	O	I-NP	O
20	31	demineralization	NN	O	I-NP	O
20	32	.	.	O	O	O

21	0	Unlike	IN	O	B-PP	O
21	1	other	JJ	O	B-NP	O
21	2	drugs	NNS	O	I-NP	O
21	3	COMMA	COMMA	O	O	O
21	4	Casodex	NNP	O	B-NP	O
21	5	doesn	NN	O	I-NP	O
21	6	't	NN	O	I-NP	O
21	7	interfere	VB	O	B-VP	O
21	8	with	IN	O	B-PP	O
21	9	the	DT	O	B-NP	O
21	10	production	NN	O	I-NP	O
21	11	of	IN	O	B-PP	O
21	12	the	DT	O	B-NP	O
21	13	male	JJ	O	I-NP	O
21	14	hormone	NN	O	I-NP	B-Medical
21	15	testosterone	NN	O	I-NP	O
21	16	COMMA	COMMA	O	O	O
21	17	but	CC	O	O	O
21	18	blocks	VBZ	O	B-VP	O
21	19	it	PRP	O	B-NP	O
21	20	from	IN	O	B-PP	O
21	21	interacting	VBG	O	B-VP	O
21	22	with	IN	O	B-PP	O
21	23	cancer	NN	O	B-NP	B-Medical
21	24	cells	NNS	O	I-NP	O
21	25	within	IN	O	B-PP	O
21	26	the	DT	O	B-NP	O
21	27	prostate	NN	O	I-NP	B-Jour
21	28	COMMA	COMMA	O	O	O
21	29	Sarosdy	NNP	O	B-NP	B-Peop
21	30	said	VBD	O	B-VP	O
21	31	.	.	O	O	O

22	0	Thompson	NNP	O	B-NP	B-Peop
22	1	is	VBZ	O	B-VP	O
22	2	also	RB	O	I-VP	O
22	3	trying	VBG	O	I-VP	O
22	4	to	TO	O	I-VP	O
22	5	determine	VB	O	I-VP	O
22	6	whether	IN	O	O	O
22	7	interrupting	VBG	O	B-VP	O
22	8	long-term	JJ	O	B-NP	O
22	9	hormone	NN	O	I-NP	B-Medical
22	10	therapy	NN	O	I-NP	B-Medical
22	11	might	MD	O	B-VP	O
22	12	actually	RB	O	I-VP	O
22	13	improve	VB	O	I-VP	O
22	14	outcome	NN	O	B-NP	O
22	15	for	IN	O	B-PP	O
22	16	patients	NNS	O	B-NP	O
22	17	.	.	O	O	O

23	0	``	``	O	O	O
23	1	If	IN	O	O	O
23	2	you	PRP	O	B-NP	O
23	3	need	VBP	O	B-VP	O
23	4	hormonal	JJ	O	B-NP	B-Medical
23	5	therapy	NN	O	I-NP	B-Medical
23	6	you	PRP	O	B-NP	O
23	7	start	VBP	O	B-VP	O
23	8	it	PRP	O	B-NP	O
23	9	and	CC	O	O	O
23	10	it	PRP	O	B-NP	O
23	11	continues	VBZ	O	B-VP	O
23	12	forever	RB	O	O	O
23	13	with	IN	O	B-PP	O
23	14	metastatic	JJ	O	B-NP	O
23	15	diseaseCOMMA	NN	O	I-NP	O
23	16	''	''	O	I-NP	O
23	17	Thompson	NNP	O	I-NP	B-Peop
23	18	said	VBD	O	B-VP	O
23	19	.	.	O	O	O

24	0	``	``	O	O	O
24	1	There	EX	O	B-NP	O
24	2	are	VBP	O	B-VP	O
24	3	side	NN	O	B-NP	O
24	4	effects	NNS	O	I-NP	O
24	5	from	IN	O	B-PP	O
24	6	that	DT	O	B-NP	O
24	7	_	NN	O	O	O
24	8	osteoporosis	NN	O	O	B-Medical
24	9	COMMA	COMMA	O	O	O
24	10	anemia	NN	O	B-NP	O
24	11	COMMA	COMMA	O	I-NP	O
24	12	mood	NN	O	I-NP	O
24	13	changes	NNS	O	I-NP	O
24	14	.	.	O	O	O

25	0	My	PP$	O	O	O
25	1	old	JJ	O	B-NP	O
25	2	professor	NN	O	I-NP	B-ProfTitle
25	3	told	VBD	O	B-VP	O
25	4	me	PRP	O	B-NP	O
25	5	it	PRP	O	B-NP	O
25	6	takes	VBZ	O	B-VP	O
25	7	the	DT	O	B-NP	O
25	8	wind	NN	O	I-NP	O
25	9	out	IN	O	B-PP	O
25	10	of	IN	O	B-PP	O
25	11	your	PP$	O	B-NP	O
25	12	sails	NNS	O	I-NP	O
25	13	.	.	O	O	O

26	0	``	``	O	O	O
26	1	We	PRP	O	B-NP	O
26	2	have	VBP	O	B-VP	O
26	3	evidence	NN	O	B-NP	O
26	4	that	IN	O	O	O
26	5	you	PRP	O	B-NP	O
26	6	don	VB	O	B-VP	O
26	7	't	NN	O	B-NP	O
26	8	need	VBP	O	B-VP	O
26	9	to	TO	O	I-VP	O
26	10	do	VB	O	I-VP	O
26	11	it	PRP	O	B-NP	O
26	12	continuously	RB	O	O	O
26	13	COMMA	COMMA	O	O	O
26	14	that	IN	O	O	O
26	15	it	PRP	O	B-NP	O
26	16	can	MD	O	B-VP	O
26	17	be	VB	O	I-VP	O
26	18	intermittent	JJ	O	O	B-Medical
26	19	.	.	O	O	O

27	0	It	PRP	O	B-NP	O
27	1	may	MD	O	B-VP	O
27	2	have	VB	O	I-VP	O
27	3	all	DT	O	B-NP	O
27	4	sorts	NNS	O	I-NP	O
27	5	of	IN	O	B-PP	O
27	6	benefits	NNS	O	B-NP	O
27	7	to	TO	O	B-PP	O
27	8	the	DT	O	B-NP	O
27	9	patient	NN	O	I-NP	B-Medical
27	10	in	IN	O	B-PP	O
27	11	terms	NNS	O	B-NP	O
27	12	of	IN	O	B-PP	O
27	13	side	NN	O	B-NP	O
27	14	effects	NNS	O	I-NP	O
27	15	of	IN	O	B-PP	O
27	16	treatment	NN	O	B-NP	O
27	17	.	.	O	O	O

28	0	And	CC	O	O	O
28	1	there	EX	O	B-NP	O
28	2	are	VBP	O	B-VP	O
28	3	some	DT	O	B-NP	O
28	4	data	NNS	O	I-NP	O
28	5	that	WDT	O	B-NP	O
28	6	suggests	VBZ	O	B-VP	O
28	7	it	PRP	O	B-NP	O
28	8	may	MD	O	B-VP	O
28	9	be	VB	O	I-VP	O
28	10	actually	RB	O	O	O
28	11	beneficial	JJ	O	O	O
28	12	at	IN	O	B-PP	O
28	13	reducing	VBG	O	B-VP	O
28	14	the	DT	O	B-NP	O
28	15	development	NN	O	I-NP	O
28	16	of	IN	O	B-PP	O
28	17	hormone-resistant	JJ	O	B-NP	O
28	18	prostate	NN	O	I-NP	B-Jour
28	19	cancer	NN	O	I-NP	B-Medical
28	20	.	.	O	O	O
28	21	''	''	O	O	O
